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Background: The purpose of this study was to determine whether brain metastases from HER2-positive
breast cancer could be detected noninvasively using positron emission tomography (PET) with 64Cu-1,4,7,
10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-trastuzumab.
Methods: PET was performed on five patients with brain metastases from HER2-positive breast cancer, at 24 or 48 h
after the injection of approximately 130 MBq of the probe 64Cu-DOTA-trastuzumab. Radioactivity in metastatic brain
tumors was evaluated based on PET images in five patients. Autoradiography, immunohistochemistry (IHC), and liquid
chromatography-tandem mass spectrometry (LC-MS/MS) analysis were performed in one surgical case to confirm HER2
specificity of 64Cu-DOTA-trastuzumab.
Results: Metastatic brain lesions could be visualized by 64Cu-DOTA-trastuzumab PET in all of five cases, which might
indicated that trastuzumab passes through the blood-brain barrier (BBB). The HER2 specificity of 64Cu-DOTA-trastuzumab
was demonstrated in one patient by autoradiography, immunohistochemistry, and LC-MS/MS.
Conclusions: Cu-DOTA-trastuzumab PET could be a potential noninvasive procedure for serial identification of metastatic
brain lesions in patients with HER2-positive breast cancer.
Trial registration: UMIN000004170
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Many novel molecular targets for anticancer treatment have
been discovered. Targeting of HER2 with the monoclonal
antibody trastuzumab is a well-established therapeutic strat-
egy for HER2-positive breast cancer in neoadjuvant [1], ad-
juvant [2], and metastatic settings [3]. Thus, it is important
to examine HER2 expression in primary tumor and meta-
static sites to determine whether anti-HER2 therapy is
indicated.
Although HER2 expression is routinely determined
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in any medium, provided the original work is phybridization (FISH) [4], technical problems can arise
when lesions are not easily accessible by core needle bi-
opsy [5]. In addition, HER2 expression can vary during the
course of the disease [6] and even among tumor lesions in
the same patient [7]. To overcome these problems, a novel
molecular imaging technique using positron emission
tomography (PET) with 124I-, 89Zr-, or 64Cu-labeled anti-
bodies has been studied for the noninvasive evaluation of
HER2 expression [8-10].
In a previous study, we reported the production of 64Cu-
labeled trastuzumab, specifically 64Cu-1,4,7,10-tetraazacy-
clododecane-1,4,7,10-tetraacetic acid (DOTA)-trastuzumab
and that 64Cu-DOTA-trastuzumab PET imaging could de-
tect primary HER2-positive breast cancer and metastatic le-
sions [10]. This imaging technique can be used to seriallyan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ment and also to evaluate patients with metastatic brain tu-
mors that are not easily accessible by core needle biopsy.
In this study, we demonstrated that 64Cu-DOTA-tras-
tuzumab PET imaging could visualize metastatic brain
lesions and confirmed the HER2 specificity of 64Cu-
DOTA-trastuzumab by means of autoradiography, IHC,
and liquid chromatography-tandem mass spectrometry
(LC-MS/MS).Methods
Patients
The patients included in this study had histologically
confirmed invasive HER2-positive (IHC 3+ or FISH-
positive) breast carcinoma with at least one site of meas-
urable brain metastasis, Eastern Cooperative Oncology
Group performance status (PS) of 0 to 1, adequate organ
function (neutrophil count ≥1,500/μL, platelet count
≥75,000/μL, hemoglobin concentration ≥9.0 g/dL, serum
bilirubin ≤1.5 mg/dL, AST and ALT ≤100 IU/L, serum
creatinine ≤1.5 mg/dL, baseline left ventricular ejection
fraction (LVEF) >60%) and were aged between 20 and
75 years. The main exclusion criteria were congestive
heart failure, uncontrolled angina pectoris, arrhythmia,
symptomatic infectious disease, severe bleeding, pulmon-
ary fibrosis, obstructive bowel disease or severe diarrhea,
and symptomatic peripheral or cardiac effusion.Preparation of 64Cu-DOTA-trastuzumab and PET/CT
protocol
64Cu-DOTA-trastuzumab was prepared as described pre-
viously [10]. Briefly, the 64Ni (p, n) 64Cu nuclear reaction
was performed with 12-MeV proton irradiation using a
small medical cyclotron (HM-12S, Sumitomo Heavy Indus-
tries Ltd., Tokyo, Japan). The beam current used was ap-
proximately 20 μA (3 h). After purification of trastuzumab
IgG (Herceptin®; Chugai Pharmaceutical Co., Ltd, Tokyo,
Japan) by ultrafiltration (Amicon Ultra 0.5 mL 50 k) with
phosphate-buffered saline (PBS), the trastuzumab in PBS
was added to DOTA mono N-hydroxysuccinimide ester
(Macrocyclics Inc., Dallas, TX, USA) and dissolved in
water. After incubation at 40°C for 3 h, crude DOTA-
trastuzumab was purified with PBS by using a PD-10 col-
umn. The PBS buffer, including DOTA-trastuzumab
(100 μg, 0.7 nmol), was exchanged for a sodium acetate
buffer (100 mM, pH 6.5) by filtration. 64Cu-DOTA-trastu-
zumab was prepared by adding 64CuCl2 to the acetate buf-
fer solution containing DOTA-trastuzumab and incubating
the solution for 1 h at 40°C. The reaction mixture was ster-
ilized by filtration through a 0.22-μm Millex GV filter
(Merck Millipore, Billerica, MA, USA). The radiolabeling
results revealed that the specific activity and radiochemical
purity were approximately 350 GBq/μmol and 98%,respectively. Approximately 500 MBq of the final product
was obtained by a single radiosynthesis.
PET/CT studies were performed at 1, 24, and 48 h after
64Cu-DOTA-trastuzumab injection with a Discovery 600
(GE Healthcare, Pewaukee, WI, USA), as described previ-
ously [10]. PET image evaluation and quantification of the
maximum single-voxel standardized uptake value (SUV-
max) were performed using AW Volume Share 4.5 soft-
ware (GE Healthcare). Regions of interest (ROIs) were
delineated within the tumor on the PET/CT images, and
the SUVmax was determined. For the background uptake,
ROIs were placed within the opposite side of normal
brain, and the SUVmax was measured.
Autoradiography, IHC, and LC-MS/MS
One patient (patient no. 5), who had a solitary brain me-
tastasis in the left cerebellum and had planned to undergo
surgery, agreed to participate in this study. 64Cu-DOTA-
trastuzumab injection was performed 1 day prior to PET
imaging and subsequent surgical resection. A 20-μm-thick
frozen section was immediately prepared from the tumor
specimen and used as a sample for autoradiography and
IHC, and a 10-μm-thick frozen section was prepared for
LC-MS/MS analysis. The residual tissue was fixed and
used for routine histopathological diagnosis.
For autoradiography, the frozen section was placed on
an imaging plate (BAS IP SR 2025, GE healthcare) for
48 h at 4°C to detect the location of radioactivity in the
specimen, and the exposed imaging plate then was read
with a FLA 9000 laser scanner system (GE Healthcare).
IHC staining was also performed on the cryosection adja-
cent to that used for autoradiography to assess the spatial
distribution of 64Cu-DOTA-trastuzumab. The HercepT-
est™ kit (DAKO, Glostrup, Denmark) was used for detec-
tion of HER2-positive tumor cells. Digitization and
registration of corresponding images from the autoradio-
gram and IHC were performed using a microcomputer
system and ImageQuant TL Analysis Toolbox software
(GE Healthcare).
To measure the exposure levels of trastuzumab in
tumor and non-tumor tissue sites, the relative amount of
complementarity-determining region (CDR) analyte was
estimated by using a laser capture micro-dissection system
(LCM; LMD7000, Leica, Buffalo Grove, IL, USA) and LC-
MS/MS system (LC; Nexera HPLC system, Shimadzu,
Chestnut Ridge, NY, USA; MS; QTRAP 4500, AB SCIEX,
Framingham, MA, USA). The schematic structure of the
trastuzumab antibody and the structural locations of the
CDR and Fc receptor (FCR) are shown in Figure 1. In
brief, the dehydrated tumor sections were stained with
hematoxylin and eosin (HE). Individual tumor and non-
tumor regions were visually dissected using LCM. The
captured tissues were dissolved in 8 M urea, and the
amount of protein was analyzed by BCA protein assay kit
Figure 1 Schematic structure of trastuzumab antibody and the locations of FCR and CDR (red).
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crude solutions were treated with reduction by tris-(2-cor-
boxyethyl)-phosphine hydrochloride, alkylation by iodoa-
cetamide, and fragmentation by trypsin at 37°C for 12 h.
The peptide-containing reaction mixtures were dissolved
in 0.1% formic acid and used as samples for LC-MS/MS.
Since the CDR in the trastuzumab heavy chain was
digested as a specific peptide (DTYIHWVR, m/z 545.3 de-
tected as a doubly charged ion), this peptide was set as the
target analyte in LC-MS/MS (MRM mode, transition was
545.3 > 597.3).General
All chemical reagents were obtained from commercial
sources. This study was conducted according to a proto-
col approved by the institutional review board and inde-
pendent ethics committee of the National Cancer Center
Hospital. All patients signed a written informed consent
form.Results and discussion
Patient characteristics
Between December 2010 and November 2013, five pa-
tients were enrolled in the current study. The median
age of the patients was 59 years. Histologically, tumors
were invasive ductal breast carcinoma, of either the solid
tubular or scirrhous type. Four patients had HER2-
positive tumors that were IHC 3+, whereas one patient
had a HER2-positive tumor that was both IHC 2+ and
FISH positive. One patient (patient no. 5) with a meta-
static brain tumor underwent a 24-h PET imaging study,
after which the tumor was surgically resected (Table 1).The mean and standard deviation of the administrated
mass of 64Cu-DOTA-trastuzumab was 74.4 ± 6.8 μg
(range, 67.8 to 80.6 μg). The mean administered activity
was 141 ± 8 MBq (range, 133 to 148 MBq).
The administration of 64Cu-DOTA-trastuzumab was
well tolerated by all subjects. No infusion- or drug-
related adverse events were reported in any of the pa-
tients. No clinically important trends indicative of safety
issues were noted in the laboratory parameters, vital
signs, or electrocardiogram parameters.
PET imaging
In 5 patients, 20 metastatic brain lesions including 7 lesions
larger than 1 cm diameter and 13 lesions smaller than 1 cm
diameter were previously identified by CT or magnetic res-
onance imaging (MRI). In this study, all of the HER2-
positive brain lesions larger than 1 cm diameter could be
seen on the 64Cu-DOTA-trastuzumab PET scan at 24 and
48 h after injection. On the other hand, 10 of 13 metastatic
brain tumors smaller than 1 cm diameter were not easily
identified by 64Cu-DOTA-trastuzumab PET imaging
(Table 1). Typical images of the lesions that could be de-
tected by both MRI and 64Cu-DOTA-trastuzumab PET,
and the lesion that could not be identified by 64Cu-DOTA-
trastuzumab PET were demonstrated in Figure 2 (white
arrow and red arrow). The limited spatial resolution of PET
leads to partial volume effects and, consequently, to limited
signal recovery for SUVmax, which is affected for small
structures. This could be one of the explanations why tu-
mors smaller than 1 cm diameter were not identified by
64Cu-DOTA-trastuzumab PET. The location, SUVmax,
background uptake, and TNR of each lesion visualized by
64Cu-DOTA-trastuzumab PET are summarized in Table 2.
Table 1 Patient characteristics
Number Age (y) Histology IHC History of trastuzumab
treatment
Number of lesions (φ <1 cm)
detected by MRI/CT/64Cu
Number of lesions (φ >1 cm)
detected by MRI/CT/64Cu
1 73 IDC-st 3+ Weekly 2/0/0 4/4/4
2 75 IDC-sc 3+ Weekly 0/0/0 1/0/1
3 65 IDC-sc 3+ Weekly 8/0/2 0/0/0
4 54 IDC-sc 3+ Tri-weekly 3/0/1 1/1/1
5 61 IDC-sc 3+ Weekly 0/0/0 1/1/1
y, years; IDC-st, invasive ductal carcinoma-solid tubular; IDC-sc, invasive ductal carcinoma-scirrhous; 64Cu, 64Cu-DOTA-trastuzumab PET; Weekly, 2 mg/kg/week;
Tri-weekly, 8 mg/kg/3 week.
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was higher at 48 h than at 24 h after injection in four cases.
In the other one case, 64Cu-DOTA-trastuzumab PET im-
aging at 48 h after injection was not carried out because of
surgical resection. Since non-specific background uptakes
in corresponding normal brain tissues were very low,
tumor-to-normal tissue count ratios (TNR) were high
(Table 2), resulting in good contrast for detecting brain me-
tastases. The average TNR values at 24 h and 48 h were
6.7 ± 2.1 and 9.8 ± 3.3, respectively.
The balance between the uptake in the tumor, blood
clearance of injected 64Cu-DOTA-trastuzumab, and the
radioactive decay of 64Cu indicate the plausible imaging
time of 48 h after the injection. Compared to an optimal
imaging time of 4 to 5 days after 89Zr-trastuzumab injec-
tion [9], imaging time of 48 h after 64Cu-DOTA-trastuzu-
mab injection seems to be more acceptable in clinical
practice. Because of its relatively longer half-life, 89Zn-tras-
tuzumab provides clearer images as the patient can be im-
aged at longer time points; however, it induces higher
radiation exposure. On the other hand, the shorter half-
life of 64Cu induces lower radiation exposure; however, itFigure 2 64Cu-DOTA-trastuzumab PET images of metastatic brain tum
white arrows show the metastatic brain tumors. Upper panels: 64Cu-DOTA-tra
MRI images. White arrows indicate metastatic brain lesions detectable by both
detectable by MRI but not by 64Cu-DOTA-trastuzumab PET. In patient no. 2 PEprovides images with non-specific activity in the blood
[10]. One possible approach to decrease the high uptake
of the probe by the liver could be to use cold trastuzumab
with 64Cu-DOTA-trastuzumab injection. However, ad-
equate interval from pre-dosing of the cold trastuzumab
should be determined in the future study.
HER2 specificity of 64Cu-DOTA-trastuzumab in a human
subject
In patient no. 5, a metastatic brain tumor of 2.8 × 3.1 cm
was visualized by 64Cu-DOTA-trastuzumab PET imaging
at 24 h after injection (Figure 2). PET imaging was not
performed at 48 h after injection in this case because of
the scheduled surgical operation. An autoradiogram of
the frozen section prepared from the removed brain
tumor specimen revealed high accumulation in the area
where HER2-positive cells were seen by IHC (Figure 3),
confirming the HER2 specificity of 64Cu-DOTA-trastu-
zumab PET imaging in a human subject.
For LC-MS/MS analysis, the tumor and non-tumor
areas were dissected by LCM (Figure 4A). The non-tumor
area consisted mainly of necrotic tissue. The proteinors in patients with HER2-positive primary breast tumors. The
stuzumab PET images; lower panels: Gd-DTPA-enhanced T1-weighted
MRI and 64Cu-DOTA-trastuzumab PET, and a red arrow indicates a lesion
T image, non-specific high uptake in blood was noted.






Location SUVmax (tumor/BG) TNR
24 h 48 h 24 h 48 h
1 1 Rt-cerebellum 1.4/0.2 2.1/0.2 9.3 12.5
2 Rt-cerebellum 1.3/0.2 2.1/0.2 8.7 12.4
3 Vermis 1.4/0.2 2.1/0.2 9.1 12.4
4 Lt-cerebellum 1.1/0.2 1.6/0.2 7.1 11.8
2 5 Lt-cerebellum 1.2/0.1 2.1/0.2 8.2 12.2
3 6 Lt-frontal 0.7/0.2 1.0/0.2 4.1 5.5
7 Lt-frontal 0.6/0.2 0.7/0.2 3.3 4.1
4 8 Lt-frontal 0.9/0.2 1.6/0.2 5.8 9.2
9 Rt-cerebellum 0.8/0.2 1.2/0.2 5.1 7.8
5 10 Lt-cerebellum 1.1/0.2 NA/NA 6.1 NA
64Cu-DOTA-trastuzumab PET imaging at 48 h after injection was not carried
out because of surgical resection.
BG, background; NA, inpatient no. 5.
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and 21 μg by BCA assay, respectively. The analyte peak
area of CDR in the tumor area was significantly higher
than that in the non-tumor area. The CDR analyte count
ratio for tumor versus non-tumor areas was calculated to
be 11:1 (Figure 4B).
This study accumulated safety data and demonstrated
clinical cases of brain metastases visualized by 64Cu-Figure 3 Histological distributions of 64Cu-radioactivity and HER2-pos
column: autoradiography. Loupe images (upper panels) show identical dist
HE stain, IHC, and autoradiography samples. Magnified images (lower pane
tumor cells.DOTA-trastuzumab PET imaging. We confirmed the
HER2 specificity of 64Cu-DOTA-trastuzumab by auto-
radiography, IHC, and LC-MS/MS in one case of meta-
static brain tumor resection.
In clinical settings, it is not possible to obtain meta-
static brain tissue samples without surgery. However,
brain metastasis is documented in 10% to 16% of pa-
tients with metastatic breast cancer during the course of
their disease [11,12] and in 40% of patients during the
course of herceptin treatment [13]. The IHC profiles of
metastatic brain tumors from breast cancer have been
reported to differ from the primary site in a certain fre-
quency [14]. Some cases of HER2-positive breast cancer
may have HER2-negative brain metastasis, and the con-
verse is also true. Furthermore, since brain metastases
generally occur late in the course of metastatic breast
cancer, one result of the improving overall survival rate
in these patients is that the incidence of brain metastasis
will likely increase [15]. Knowing the HER2 status of a
metastatic brain tumor would assist in identifying the
best additional systemic treatment. 64Cu-DOTA-trastu-
zumab PET imaging is a potential solution for noninva-
sively and serially evaluating brain tumor HER2 status.
Although it is generally considered that trastuzumab
poorly penetrates the blood-brain barrier (BBB), we were
able to visualize brain lesions in this study. Therapeutic
antibodies such as trastuzumab are thought to be too largeitive tumor cells. Left column: HE staining; middle column: IHC; right
ribution of radioactivity and location of HER2-positive tumor cells for
ls, ×200) confirmed the radioactivity and HER2-positive status of
Figure 4 Relative amount of trastuzumab-specific CDR in tumor cell regions and non-tumor cell regions. (A) HE staining. Tumor regions
(inside solid lines) and non-tumor regions (inside dashed lines) were dissected individually by LCM and collected. (B) The relative amount of
trastuzumab-specific CDR. LC-MS/MS analysis revealed that the target peptide (DTYIHWVR, m/z 545.3 detected as a doubly charged ion) in tumor
cell regions was 11-fold higher than that in non-tumor cell regions.
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tration of the tumor by monoclonal antibodies may be hin-
dered by increased intratumoral interstitial pressure
[18-20]. In this study, however, high CNS penetration of
64Cu-DOTA-trastuzumab was demonstrated by LC-MS/
MS with an 11-fold higher CDR analyte count in the
tumor cell region than the non-tumor cell region and by
PET imaging with a TNR of 5 to 12 at 48 h after injection.
Another study using 89Zr-trastuzumab PET imaging also
demonstrated CNS penetration in patients with metastatic
brain tumors, with an 18-fold higher uptake in brain tu-
mors than in normal brain tissue at 4 to 7 days after injec-
tion [9]. Some researchers have reported that this
increased penetration is likely due to disruption or com-
promise of the BBB at the site of brain metastasis by the
metastatic tumor itself or by cancer therapies such as
radiotherapy [21,22], though one report suggested that the
BBB in HER2-positive tumors was disrupted less than in
triple-negative or basal-type breast cancer [23]. Another
potential mechanism for transporting trastuzumab across
the BBB is the FCR for immunoglobulin G, which
expressed on vessels in the brain [24]. However, further
studies are needed to clarify the mechanisms involved in
transportation across the BBB in tumor sites.
PET imaging with 64Cu-DOTA-trastuzumab has the
potential to characterize HER2 status using a potent
quantitative biomarker that can predict the biological ef-
fect of anti-HER2 antibodies. This information might
help clinicians determine the optimal HER2 inhibitor
therapy for each individual. In this study there was high
accumulation in the normal liver. The SUVmax in the
liver at 24 h and 48 h post-injection ranged 5.1 to 8.2and 5.2 to 8.0, respectively, which may interrupt to de-
tect occult liver metastasis. The high accumulation in
normal liver is likely due to high expression of FCR on
liver sinusoidal endothelial cell [25]. Another research
group reported that 50 mg of trastuzumab reduced liver
uptake of 64Cu-DOTA-trastuzumab in HER2-positive
metastatic breast cancer [26]. These findings demon-
strate that 64Cu-DOTA-trastuzumab PET/CT might be
applicable not only for breast cancer, but for other kinds
of HER2-positive malignancies as well.
In this study, HER2 specificity of 64Cu-DOTA-trastu-
zumab was demonstrated for one case. The HER2-
positive status of the tumor was confirmed by IHC, high
radioactivity was shown in the area of HER2-positive
tumor cells by autoradiography, LC-MS/MS revealed an
11-fold higher trastuzumab CDR amount in the tumor
cell region than in the non-tumor region, and the aver-
age TNR of 64Cu-DOTA-trastuzumab PET imaging at
48 h was 9.8 ± 3.3. These results strongly suggest the
HER2 specificity of 64Cu-DOTA-trastuzumab imaging.
However, for the other four cases, we could not confirm
the HER2 status of metastatic brain tumors because they
did not undergo surgery. This is a potential weakness of
our study, but in general, it is difficult to sample meta-
static brain tumors by surgical operation because pa-
tients with HER2-positive breast cancer and metastatic
brain tumors are usually treated with systemic chemo-
therapy. To confirm HER2 specificity of 64Cu-DOTA-
trastuzumab PET imaging in humans, more cases of
both HER2-positive and HER2-negative tumors are re-
quired, along with further study comparing the results of
PET imaging with HER2 status.
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64Cu-DOTA-trastuzumab PET imaging was safe and
feasible for outpatients. This technique can be used to
visualize metastatic brain lesions in HER2-positive breast
cancer patients. HER2 specificity of 64Cu-DOTA-trastu-
zumab was demonstrated in a surgical resection case by
means of autoradiography, IHC, and LC-MS/MS. To
evaluate, 64Cu-DOTA-trastuzumab is a promising candi-
date for the noninvasive and serial evaluation of HER2
status in metastatic brain tumors.
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